VBIV - VBI Vaccines Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.88
-0.05 (-1.71%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.93
Open2.96
Bid2.79 x 1200
Ask3.07 x 1100
Day's Range2.80 - 2.96
52 Week Range2.56 - 5.10
Volume136,967
Avg. Volume300,295
Market Cap184.941M
Beta1.48
PE Ratio (TTM)N/A
EPS (TTM)-0.85
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.30
Trade prices are not sourced from all markets
  • GlobeNewswire8 days ago

    VBI Vaccines to Participate in the 2018 Oppenheimer Boston Oncology Insight Summit

    CAMBRIDGE, Mass., July 09, 2018-- VBI Vaccines Inc., a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that the company ...

  • GlobeNewswire28 days ago

    VBI Vaccines to Present at 2018 JMP Securities Life Sciences Conference

    VBI Vaccines Inc. (VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that Jeff Baxter, President and CEO, will present at the JMP Securities Life Sciences Conference on Thursday, June 21, 2018, at 10:30 a.m. ET at the St. Regis Hotel in New York. VBI Vaccines Inc. (“VBI”) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology.

  • GlobeNewswire2 months ago

    VBI Vaccines Announces Results of Annual General Meeting

    CAMBRIDGE, Mass., May 25, 2018-- VBI Vaccines Inc., a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the voting results ...

  • GlobeNewswire2 months ago

    Well Leveraged: VBI Vaccines Outlines Clinical Trial Progress

    Jeff Baxter, President and CEO of VBI Vaccines Inc. (VBIV), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, took time to update WSA’s investor audience regarding the company’s top 3 clinical programs. Mr. Baxter discussed the progress since his last conversation with WSA from October 2017, “At the end of October, we completed a very successful financing…[of] $72 million.

  • ACCESSWIRE2 months ago

    Wired News – VBI Vaccines Reports Positive Data from Final Phase-1 Study for Preventative CMV Vaccine

    LONDON, UK / ACCESSWIRE / May 14, 2018 / If you want access to our free research report on VBI Vaccines Inc. (NASDAQ: VBIV), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=VBIV as the Company's latest news hit the wire. On May 10, 2018, the commercial-stage biopharmaceutical Company, which develops next generation vaccines to address unmet needs in infectious disease and immuno-oncology, reported positive results from the randomized, placebo-controlled Phase-1 study of VBI-1501. Active-Investors.com is currently working on the research report for Adaptimmune Therapeutics PLC (NASDAQ: ADAP), which also belongs to the Healthcare sector as the Company VBI Vaccines.

  • GlobeNewswire2 months ago

    VBI Vaccines Announces Positive Final Phase 1 Study Results of Preventative CMV Vaccine

    VBI Vaccines Inc. (VBIV) (“VBI”), today announced positive final top-line results from the randomized, placebo-controlled Phase 1 study of VBI-1501, the company’s prophylactic cytomegalovirus (CMV) vaccine candidate. VBI-1501 was developed using the company’s proprietary enveloped virus-like particle (eVLP) technology and presents a modified form of the glycoprotein B (gB) found on CMV.

  • GlobeNewswire3 months ago

    VBI Vaccines Announces First Quarter 2018 Financial Results and Provides Corporate Update

    --Enrollment completed in PROTECT Phase 3 clinical study of Sci-B-Vac ® Hepatitis B Vaccine--. --Key upcoming milestones in 2018 for lead eVLP vaccine candidates, VBI-1501 for prevention of Congenital ...

  • ACCESSWIRE3 months ago

    Blog Exposure - VBI Vaccines Announced Dosing of Last Patient in PROTECT Phase-3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine

    Stock Monitor: KemPharm Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 23, 2018 / Active-Investors.com has just released a free research report on VBI Vaccines Inc. (NASDAQ: VBIV ). If you want ...

  • GlobeNewswire3 months ago

    VBI Vaccines Announces Completion of Enrollment in PROTECT Phase 3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine

    The PROTECT study is one of two ongoing global studies that form the Phase 3 program for Sci-B-Vac®.  It is designed to evaluate the safety and immunogenicity of Sci-B-Vac® compared with the control vaccine, Engerix-B®, in support of future regulatory filings in the U.S., Europe, and Canada. Sci-B-Vac is currently approved for use in Israel and in 14 other countries.

  • Benzinga4 months ago

    ICYMI: Penny Stocks, Energy ETF, AR And VR Devices

    In case you missed it, here are some of Benzinga's top stories from Thursday, March 15th, 2018. Energy Stocks And ETFs Struggle For energy investors, the weakness in energy stocks and ETFs that characterized ...

  • Capital Cube7 months ago

    ETFs with exposure to VBI Vaccines, Inc. : December 26, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to VBI Vaccines, Inc. Here are 5 ETFs with the largest exposure to VBIV-US. Comparing the performance and risk of VBI Vaccines, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • VBI Vaccines, Inc. :VBIV-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
    Capital Cube7 months ago

    VBI Vaccines, Inc. :VBIV-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017

    Categories: Yahoo FinanceGet free summary analysis VBI Vaccines, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of VBI Vaccines, Inc. – Pieris Pharmaceuticals, Inc. and PDL BioPharma, Inc. (PIRS-US and PDLI-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 0.19 ... Read more (Read more...)

  • Benzinga8 months ago

    VBI Vaccines Could Nearly Triple In Value On New Drug Launches, According To BMO

    VBI Vaccines, Inc. - Ordinary Shares (NASDAQ: VBIV ) will release results on three clinical trials in the first half of 2018, presenting certain investment opportunities of an uncertain nature. Some on ...

  • VBI: Multiple Platforms Yield a Portfolio of Vaccines
    Zacks Small Cap Research8 months ago

    VBI: Multiple Platforms Yield a Portfolio of Vaccines

    NASDAQ:VBIV VBI Vaccines, Inc. (NASDAQ:VBIV) is a Cambridge, Massachusetts-based biopharmaceutical company developing a portfolio of vaccines including solutions for hepatitis B, cytomegalovirus (CMV) ...